The pace of enzyme catalyst development is fast becoming a key constraint in biomanufacturing. Creative Enzymes, a global enzyme technology service provider, recently launched an AI-integrated platform that takes a systematic approach to the problem. By merging computational enzyme engineering with hands-on process development know-how, the platform delivers AI-Driven Biocatalysis Solutions that are not only predictable in silico but also practical in the real world—stable at industrial scale and economically sound.While biocatalysis is an established manufacturing process, a significant gap remains between the identification of application opportunities and the availability of suitable enzymes. Traditional development approaches are ill-equipped to meet the speed requirements of iterative product development. AI brings critical value on three fronts: predicting enzyme candidates best suited for a given biocatalytic reaction; designing enzymes constrained by process parameters rather than biological factors; and leveraging key molecular features to anticipate process performance in advance.

The benefits of a biocatalyst-based approach are not limited to speed and efficiency. AI techniques also reduce the need to experiment with and test a myriad of biocatalyst variants, thus saving on R&D costs. In addition, it greatly reduces the risk of process failure by identifying a suitable biocatalyst much sooner in the development process, while also opening routes to molecules that were previously inaccessible to enzymatic conversion. This opens new product opportunities and allows for the development of new biocatalytic processes.

The platform's capabilities are delivered through three specialized service modules, each tailored to different stages of biocatalyst development:

The platform delivers an end-to-end AI-driven solution for biocatalyst discovery and engineering. Its workflow spans the entire value chain—from target reaction analysis to scale-up characterization—encompassing computational screening against sequence databases and proprietary libraries, process optimization across key parameters (temperature, pH, solvent, substrate loading, and cofactor availability), and scale-up evaluation covering expression yield and operational half-life. Quantitative data is passed from each stage to the next, ensuring that development decisions are driven by empirical evidence rather than theoretical assumptions. For moderately complex targets, this structured approach reduces the "design-build-test-learn" cycle from the conventional 12–24 months to just 8–12 months.

AI-Driven Industrial Biocatalysis is closing the divide between lab-scale performance and commercial production. The platform addresses the entire journey from reaction engineering to full-scale implementation—encompassing substrate concentration optimization, cofactor regeneration, and product inhibition management; immobilization and formulation development to extend operational lifespan; integration of process analytical technology for real-time quality assurance; and the delivery of complete technology transfer packages, including SOPs and regulatory documentation. The end objective is not simply better enzymes, but a fundamentally improved industrial workflow built around the catalytic process.

AI-Driven Green Biocatalysis provides sustainability-focused solutions that align with corporate environmental goals and regulatory trends. Enzymatic reactions typically occur in aqueous media at room temperature, minimizing the use of organic solvents and associated emissions. Mild reaction conditions reduce heating and cooling requirements compared to chemically catalyzed processes. Enzymatic selectivity minimizes byproduct formation, simplifies purification, and reduces waste generation. AI-guided development amplifies these advantages by identifying enzymes that are inherently more efficient and compatible with the process, thereby reducing the environmental footprint of both the development process and final production operations.

The platform's capabilities have been demonstrated through a recent AI-driven case study in transaminase engineering. Researchers developed a 6D protein engineering framework that combines interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations with precision and reduce experimental screening efforts. Five transaminase variants selected by AI—each with nine mutations—exhibited high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes convert prochiral ketones to sitagliptin, delivering enantiomeric purity exceeding 99% and conversion rates of up to 89% during scale-up production.

Pharma is where AI biocatalysis is making its biggest splash right now—asymmetric synthesis of chiral intermediates and replacing hazardous reagents with cleaner routes are already happening. Agrochemicals and food are catching on too: the former to fine-tune toxicology profiles, the latter to deliver cleaner labels through enzymatic modification. And fine chemicals and personal care? They're starting to explore the upside—high-value conversions and milder, more sustainable processes.